Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CIRRH
MCID: LVR012
MIFTS: 63

Liver Cirrhosis (CIRRH)

Categories: Gastrointestinal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Liver Cirrhosis

About this section

MalaCards integrated aliases for Liver Cirrhosis:

Name: Liver Cirrhosis 12 74 54 44 15 37 71
Cirrhosis 12 73 54 42 15 39 71
Cirrhosis of Liver 12 29 6 17
Cirrhosis, Cryptogenic 71
Cryptogenic Cirrhosis 73
Cirrh 73

Classifications:

MalaCards categories:
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:5082
MeSH 44 D008103
NCIt 50 C2951
SNOMED-CT 67 19943007
ICD10 32 K74.60
UMLS 71 C0023890 C0267809 C1623038
Sources

Summaries for Liver Cirrhosis

About this section
MedlinePlus : 42 Cirrhosis is scarring of the liver. Scar tissue forms because of injury or long-term disease. Scar tissue cannot do what healthy liver tissue does - make protein, help fight infections, clean the blood, help digest food and store energy. Cirrhosis can lead to Easy bruising or bleeding, or nosebleeds Swelling of the abdomen or legs Extra sensitivity to medicines High blood pressure in the vein entering the liver Enlarged veins called varices in the esophagus and stomach. Varices can bleed suddenly. Kidney failure Jaundice Severe itching Gallstones A small number of people with cirrhosis get liver cancer. Your doctor will diagnose cirrhosis with blood tests, imaging tests, or a biopsy. Cirrhosis has many causes. In the United States, the most common causes are chronic alcoholism and hepatitis. Nothing will make the scar tissue disappear, but treating the cause can keep it from getting worse. If too much scar tissue forms, you may need to consider a liver transplant. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Liver Cirrhosis, also known as cirrhosis, is related to alcoholic liver cirrhosis and primary biliary cholangitis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Liver Cirrhosis is KRT8 (Keratin 8), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and FOXA2 and FOXA3 transcription factor networks. The drugs Zinc and Propofol have been mentioned in the context of this disorder. Affiliated tissues include Bone and Blood.

UniProtKB/Swiss-Prot : 73 Cirrhosis: A liver disease characterized by severe panlobular liver-cell swelling with Mallory body formation, prominent pericellular fibrosis, and marked deposits of copper. Clinical features include abdomen swelling, jaundice and pulmonary hypertension.

Wikipedia : 74 Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis, is the impaired liver function caused by... more...

Sources

Related Diseases for Liver Cirrhosis

About this section

Diseases related to Liver Cirrhosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1579)
# Related Disease Score Top Affiliating Genes
1 alcoholic liver cirrhosis 33.7 HGF GPT F2 CYP2E1 ALB AFP
2 primary biliary cholangitis 33.2 GPT GGT1 F2 ALB
3 hepatic encephalopathy 32.9 GPT F2 ALB
4 hepatitis 32.7 KRT8 IFNA1 GPT GGT1 F2 AFP
5 portal hypertension 32.7 GPT F2 ALB
6 hepatic coma 32.6 GPT F2 ALB AFP
7 cholangitis, primary sclerosing 32.6 SERPINA1 GPT GGT1 F2 ALB AFP
8 esophageal varix 32.5 SERPINA1 GPT F2 ALB AFP
9 hepatitis b 32.4 IFNA1 GPT GGT1 F2 ALB AFP
10 cryptogenic cirrhosis 32.4 LOC106096416 KRT8 HFE F2
11 hepatorenal syndrome 32.3 REN GPT F2 ALB
12 viral hepatitis 32.2 SERPINA1 KRT8 IFNA1 HFE GPT GGT1
13 portal vein thrombosis 32.1 IFNA1 F2 AFP
14 alcohol use disorder 32.1 HFE GPT GGT1 CYP2E1 ALB
15 non-alcoholic fatty liver disease 32.0 SERPINA1 HFE GPT GGT1 CYP2E1 ALB
16 liver disease 31.9 SERPINA1 MEG3 KRT8 IFNA1 HGF HFE
17 non-alcoholic steatohepatitis 31.9 HGF HFE GPT CYP2E1 ALB
18 cholestasis 31.9 SERPINA1 GPT GGT1 F2 ALB
19 hepatitis c 31.9 KRT8 IFNA1 HOTAIR HFE GPT GGT1
20 cholangitis 31.8 GPT GGT1 F2 ALB
21 alcoholic hepatitis 31.8 HGF GPT GGT1 F2 CYP2E1 ALB
22 hemochromatosis, type 1 31.8 SERPINA1 HFE GPT ALB AFP
23 acute kidney failure 31.8 REN HGF GPT F2 ALB
24 fatty liver disease 31.8 MALAT1 HFE GPT GGT1 CYP2E1
25 autoimmune hepatitis 31.7 KRT8 IFNA1 GPT GGT1 F2 ALB
26 hemosiderosis 31.7 HFE GPT ALB
27 alpha-1-antitrypsin deficiency 31.7 SERPINA1 HFE GPT F2 ALB AFP
28 cholecystitis 31.6 GPT F2 ALB
29 bilirubin metabolic disorder 31.6 GPT GGT1 F2 ALB
30 sclerosing cholangitis 31.6 GPT GGT1 F2 ALB
31 respiratory failure 31.6 SERPINA1 REN GPT F2 ALB
32 obstructive jaundice 31.5 REN HGF GPT GGT1 F2 ALB
33 schistosomiasis 31.5 GPT F2 ALB
34 pleural empyema 31.5 GPT F2 ALB
35 acute liver failure 31.4 HGF GPT F2 ALB
36 acute cystitis 31.4 REN GPT F2 ALB
37 hepatitis a 31.4 SERPINA1 IFNA1 GPT F2 ALB AFP
38 pneumonia 31.4 SERPINA1 IFNA1 GPT F2 ALB
39 exanthem 31.4 IFNA1 GPT F2 ALB
40 acute kidney tubular necrosis 31.3 REN HGF GPT F2 ALB
41 hepatitis d 31.3 IFNA1 GPT F2
42 hypothyroidism 31.3 REN IFNA1 GPT F2 ALB
43 choledocholithiasis 31.3 GPT GGT1 F2 ALB
44 siderosis 31.3 SERPINA1 HFE GPT
45 biliary atresia 31.3 HGF GPT GGT1 F2 ALB
46 tricuspid valve insufficiency 31.2 REN GPT F2 ALB
47 hepatitis e 31.2 GPT F2 ALB
48 type 2 diabetes mellitus 31.2 REN HGF HFE GPT GGT1 GAS5
49 iga glomerulonephritis 31.2 SERPINA1 REN ALB
50 disease by infectious agent 31.2 SERPINA1 IFNA1 GPT ALB

Graphical network of the top 20 diseases related to Liver Cirrhosis:



Diseases related to Liver Cirrhosis
Sources

Symptoms & Phenotypes for Liver Cirrhosis

About this section

UMLS symptoms related to Liver Cirrhosis:


nausea and vomiting, constipation, abdominal pain, diarrhea, hepatosplenomegaly, dyspepsia, icterus, heartburn, gastrointestinal gas
Sources

Drugs & Therapeutics for Liver Cirrhosis

About this section

Drugs for Liver Cirrhosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 580)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4 7440-66-6 32051
2
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
4
Magnesium oxide Approved Phase 4 1309-48-4 14792
5
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
6
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
7
Azithromycin Approved Phase 4 83905-01-5 55185 447043
8
Vancomycin Approved Phase 4 1404-90-6 441141 14969
9
Imipenem Approved Phase 4 64221-86-9, 74431-23-5 104838
10
Insulin glargine Approved Phase 4 160337-95-1
11
Insulin glulisine Approved Phase 4 207748-29-6
12
acetic acid Approved Phase 4 64-19-7 176
13
Colchicine Approved Phase 4 64-86-8 6167 2833
14
Somatostatin Approved, Investigational Phase 4 51110-01-1, 38916-34-6 53481605
15
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
16
Adefovir dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
17
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
18
Cefoxitin Approved Phase 4 35607-66-0 441199
19
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
20
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
21
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
22
Nadolol Approved Phase 4 42200-33-9 39147
23
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
24
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
25
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
26
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
27
Losartan Approved Phase 4 114798-26-4 3961
28
Abatacept Approved Phase 4 332348-12-6 10237
29
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
30
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
31
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
32
Dalteparin Approved Phase 4 9005-49-6
33
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
34
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 5281106 54677470
35
Ledipasvir Approved Phase 4 1256388-51-8 67505836
36
Methylene blue Approved, Investigational Phase 4 61-73-4
37
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
38
Nevirapine Approved Phase 4 129618-40-2 4463
39
Meperidine Approved Phase 4 57-42-1 4058
40
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
41
Nadroparin Approved, Investigational Phase 4
42
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
43
Iron Approved Phase 4 7439-89-6 23925 29936
44
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
45
Nitric Oxide Approved Phase 4 10102-43-9 145068
46
Atorvastatin Approved Phase 4 134523-00-5 60823
47
Warfarin Approved Phase 4 81-81-2 6691 54678486
48
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
49
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
50
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049

Interventional clinical trials:

(show top 50) (show all 1488)
# Name Status NCT ID Phase Drugs
1 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
2 Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B Unknown status NCT01380951 Phase 4 telbivudine
3 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
4 Rifaximin Predicts the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial Unknown status NCT02074280 Phase 4 rifaximin
5 Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial Unknown status NCT00663182 Phase 4 Entecavir
6 A Randomised Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis Unknown status NCT02238860 Phase 4 Entacavir;Tenofovir
7 Efficacy and Safety Study of Tolvaptan for Liver Cirrhotic Patients With Hyponatremia and Ascites: A Multi-center, Randomized, Double-blind, Placebo-controlled 4-weeks Clinical Trial Unknown status NCT01716611 Phase 4 Tolvaptan;placebo
8 Losartan in the Prevention of Sodium Retention and Ascites in Liver Cirrhosis - a Prospective Randomized Long-Term Study Unknown status NCT00239096 Phase 4 losartan (drug)
9 Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding Comparing Carvedilol and Endoscopic Therapy: A Multicenter Randomized Controlled Trial Unknown status NCT02695732 Phase 4 Carvedilol
10 A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Progressive Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
11 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With HCC:a Randomized Trial Unknown status NCT01298284 Phase 4 propranolol
12 Hemodynamic Effect of the Combination of Simvastatin With Non-cardioselective Beta Blockers in Patients With Cirrhosis and Clinically Significant Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
13 A Randomized Tril of Endoscopic Cyanoacrylate Obliteration vs. Nadolol Unknown status NCT00567216 Phase 4 Nadolol
14 Effect of Betablocker or Aldosterone Antagonist Therapy on Oxygenation, Peripheral and Cardiac Hemodynamics and Humoral Systems Unknown status NCT00332904 Phase 4 propranolol;spironolactone
15 The Effect of Carvedilol Vs Propranolol in Patients With Cirrhosis Related Esophagogastric Varices After Multiple Endoscopic Treatments For Secondary Prophylaxis:A Randomized Controlled Trial Unknown status NCT02385422 Phase 4 Carvedilol;Propranolol
16 Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis Unknown status NCT01693679 Phase 4 Telbivudine, Lamivudine, Adefovir ,Enecavir
17 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
18 A Prospective Randomized Controlled Trial of Efficacy and Safety of Anticoagulant Therapy With Low Molecular Weight Heparin and Warfarin in Portal Vein Thrombosis of Liver Cirrhosis Unknown status NCT04173429 Phase 4 Low molecular weight heparin (LMWH), warfarin
19 A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Liver Cirrhosis Patients Due to Hepatitis B Virus Unknown status NCT02241590 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu Tablet
20 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease (BRAVE): Korean Nation-wide Multicenter Retrospective and Prospective Observational Cohort Study Unknown status NCT02837302 Phase 4 Livact
21 Metformin Experience on Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis Unknown status NCT02470546 Phase 4 Metformin;Placebo
22 A Multi-Center Study to Assess the Efficacy and Safety of Traditional Chinese Medicine Combined With Entecavir for Patients With Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV Unknown status NCT02241616 Phase 4 Entecavir+Fuzheng Huayu+TCM Granule
23 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Liver Cirrhosis and Minimal Encephalopathy: a Single Center Placebo Control Double Blind Study Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
24 Bacterial Infections Associated With Healthcare (Healthcare-Associated) in Hospitalized Cirrhotic Patients: Randomized Study of Use of Traditional Empirical Antibiotic Therapy and Second-line Targeted at Multi-resistant Bacteria Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
25 Rifaximin Reduces the Complications of Decompensated Cirrhosis Unknown status NCT02190357 Phase 4 Rifaximin
26 Prevention of Progression of Portal Hypertension in Compensated Cirrhosis Using Selective Hepatic Vasodilators. A Double-blind, Multicenter,Randomized Controlled Trial Unknown status NCT01282398 Phase 4 Simvastatin;placebo
27 The Effect of HVPG-Guided Individualized Therapy in Patients With Cirrhosis Related Esophagogastric Variceal Hemorrhage For Secondary Prophylaxis:A Randomized Controlled Trial Unknown status NCT02638415 Phase 4 Carvedilol
28 Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy Unknown status NCT02401490 Phase 4 Human albumin;Placebo
29 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
30 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
31 Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis：A Zelen-design Multicenter Randomized Controlled Trial Unknown status NCT02630095 Phase 4 Nadroparin Calcium and Warfarin
32 Insulin Therapy in the Inpatient Management of Cirrhotic Patients With Type 2 Diabetes Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
33 The Employing of the Bio-Hep-B PreS1/PreS2/S Hepatitis B Virus (HBV) Vaccine in New Born Babies From HBV Positive Palestinian Mothers Unknown status NCT01133184 Phase 4
34 A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Unknown status NCT01965418 Phase 4 Fufang Biejia Ruangan Tablet;Placebo
35 A Zelen-design Randomized Controlled Trial of the Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Unknown status NCT02398357 Phase 4 Nadroparin Calcium and Warfarin
36 A Randomized Controlled Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis Unknown status NCT03345589 Phase 4 18-22mg/kg/d Ursodeoxycholic;13-15mg/kg/d Ursodeoxycholic
37 The Effect of Branched-chain Amino Acid on the Improvement of Serum Albumin Level in Cirrhotic Patients With Ascites: A Multi-center, Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial Unknown status NCT02755701 Phase 4 Branched-chain Amino Acid;Placebo
38 Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response Unknown status NCT01530711 Phase 4 Terlipressin and albumin
39 Propofol and Fentanyl Versus Midazolam and Fentanyl for Sedation During Diagnostic or Therapeutic Gastrointestinal Endoscopy in Cirrhotic Patients Unknown status NCT00906139 Phase 4 Propofol;Midazolam;Fentanyl
40 Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy Unknown status NCT02238444 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
41 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
42 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
43 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
44 The Protection of Telipression on Developing of Acute Kidney Injury in Cirrhotic Patients With Upper-gastroentestinal Bleeding Completed NCT04358016 Phase 4 Terlipressin;Somatostatin
45 Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis Completed NCT01265173 Phase 4 Cefotaxime;Ceftriaxone;Ciprofloxacin
46 Prospective Detection of Liver Fibrosis With MRI Compared to Fibroscan and Blood Tests Completed NCT01600105 Phase 4 Perfusion MRI
47 Phase IV Study of Long Term Peg-Intron for Patients Who Have Failed to Respond to Rebetron/Interferon With Advanced Fibrosis and Cirrhosis Secondary to Hepatitis C- The Copilot Trial Completed NCT00179413 Phase 4 PEG -Intron;Colchicine
48 Phase 4 Study on the Comparison Between Combined Versus Sequential Diuretic Treatment of Moderate Ascites in Nonazotemic Patients With Cirrhosis Completed NCT00741663 Phase 4 Spironolactone and furosemide;Spironolactone and furosemide
49 The Effect of Oral Taurine on Portal Hemodynamics in Patients With Advanced Completed NCT02344719 Phase 4 Taurin 6g per day per oral for 28 days;Placebo 6g per day per oral for 28 days
50 The SIM-SOF Trial: A Randomized Trial Comparing Simeprevir-Sofosbuvir Versus Peginterferon/Ribavirin/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype-1a-infected Patients With Cirrhosis Completed NCT02168361 Phase 4 Pegylated Interferon alfa-2b;Simeprevir;Ribavirin;Sofosbuvir

Search NIH Clinical Center for Liver Cirrhosis

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Bumetanide
Ethacrynate Sodium
Ethacrynic Acid
Furosemide
Milk thistle extract
torsemide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Cirrhosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Liver Cirrhosis:
Autologous bone marrow-derived mesenchymal stem cells for liver cirhosis
Autologous bone marrow-derived stem cells for treatment of liver cirrhosis
Autologous hematopoietic stem cells for treatment of end-stage chronic liver disease
Bone marrow-derived endothelial progenitor cells for advanced liver cirrhosis
Bone marrow-derived mesenchymal stem cells for treatment of cirrhosis-related refractory ascites
Bone marrow-derived mesenchymal stem cells for treatment of liver cirrhosis
Hepatocyte transplantation for treatment of liver failure and inherited metabolic diseases
Mesenchymal stem cells for liver cirrhosis
NU215-01, human umbilical cord mesenchymal stem cells for treatment of liver cirrhosis
Peripheral blood-derived CD34+ or mononuclear cells for liver cirrhosis
StempeucelLC, mesenchymal stem cells for liver cirrhosis
Umbilical cord-derived mesenchymal stem cells for treatment of liver cirrhosis
Embryonic/Adult Cultured Cells Related to Liver Cirrhosis:
Bone marrow-derived mesenchymal stem cells (family) PMIDs: 22121493 21771778
Peripheral blood-derived hematopoietic stem cells PMIDs: 20587151
Bone marrow-derived endothelial progenitor cells (family)
Hepatocytes
Umbilical cord-derived mesenchymal stem cells
Peripheral blood-derived hematopoietic stem cells (family)
Peripheral blood-derived mesenchymal stem cells (family)
Bone marrow-derived mesenchymal stem cells (Stempeucel) PMIDs: 18720444
Umbilical cord-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: liver cirrhosis

Sources

Genetic Tests for Liver Cirrhosis

About this section

Genetic tests related to Liver Cirrhosis:

# Genetic test Affiliating Genes
1 Cirrhosis of Liver 29
Sources

Anatomical Context for Liver Cirrhosis

About this section

MalaCards organs/tissues related to Liver Cirrhosis:

40
Liver, Bone Marrow, Spleen, Bone, Endothelial, Kidney, T Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Liver Cirrhosis:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
3 Liver Sinusoids Hepatic Stellate Cells Affected by disease
4 Liver Liver Lobule Hepatocytes Affected by disease
5 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
6 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
Sources

Publications for Liver Cirrhosis

About this section

Articles related to Liver Cirrhosis:

(show top 50) (show all 48525)
# Title Authors PMID Year
1
Mutation of human keratin 18 in association with cryptogenic cirrhosis. 61 6 54
9011570 1997
2
Keratin 8 and 18 mutations are risk factors for developing liver disease of multiple etiologies. 54 6
12724528 2003
3
Keratin 8 mutations in patients with cryptogenic liver disease. 54 6
11372009 2001
4
Effectiveness of 4-Week Oral Taurine Treatment for Muscle Cramps in Patients with Liver Cirrhosis: A Single-Arm Pilot Study. 61 42
33381931 2021
5
Challenges in measuring renal function in liver cirrhosis: are there implications in clinical practice? 42 61
33321021 2020
6
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review. 42
33336781 2020
7
Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension. 61 54
20428787 2010
8
The potential role of insulin-like growth factor 1, insulin-like growth factor binding protein 3 and bone mineral density in patients with chronic hepatitis C virus in Cairo, Egypt. 61 54
20189618 2010
9
Relationship between the expression of IP-10 and IP-10 mRNA in peripheral blood and HBV DNA level in patients with cirrhosis. 61 54
20525556 2010
10
Splanchnic concentrations and postprandial release of visceral adipokines. 54 61
19913846 2010
11
Correlation of liver stiffness and histological features in healthy persons and in patients with occult hepatitis B, chronic active hepatitis B, or hepatitis B cirrhosis. 61 54
19920809 2010
12
Hemodynamic effects of chronic smoking in liver cirrhosis: a role for adrenomedullin. 54 61
20216319 2010
13
Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure. 61 54
19582578 2010
14
Influence of transforming growth factor-beta1 gene polymorphism at codon 10 on the development of cirrhosis in chronic hepatitis B virus carriers. 54 61
20357999 2010
15
Aquaporin-2 urinary excretion in cirrhosis: relationship to vasopressin and nitric oxide. 61 54
19495975 2010
16
Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study. 61 54
20102356 2010
17
Hepatic osteodystrophy and liver cirrhosis. 54 61
20355242 2010
18
Relationship and clinical significance of TGF-beta1 expression with Treg cell infiltration in hepatocellular carcinoma. 54 61
20346216 2010
19
Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients. 61 54
20350877 2010
20
Alpha-fetoprotein gene polymorphisms and risk of HCC and cirrhosis. 61 54
19968979 2010
21
Utilization of platelet count spleen diameter ratio in predicting the presence of esophageal varices in patients with cirrhosis. 61 54
19593164 2010
22
Impact factors for microinvasion in patients with hepatocellular carcinoma: possible application to the definition of clinical tumor volume. 54 61
19406586 2010
23
Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. 54 61
19877168 2010
24
Hepatitis B virus load in serum does not reflect histologic activity in patients with decompensated cirrhosis. 54 61
19804841 2010
25
Usefulness of non-invasive markers for predicting liver cirrhosis in patients with chronic hepatitis B. 54 61
19793171 2010
26
Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism. 61 54
19864937 2010
27
Increased bactericidal/permeability increasing protein in patients with cirrhosis. 61 54
19765220 2010
28
[Relationship between quality of life and basic syndromes of traditional Chinese medicine in patients with posthepatitic cirrhosis]. 61 54
20082755 2010
29
[Expressions of MDM2 and MMP-7 in normal liver, cirrhosis, hepatocellular carcinoma tissues]. 61 54
20128976 2010
30
Potential conditions causing impairment of selective hepatobiliary enhancement of gadobenate dimeglumine-enhanced delayed magnetic resonance imaging. 54 61
20118733 2010
31
Severe sepsis in cirrhosis. 61 54
19885876 2009
32
[Monitoring patients with chronic hepatitis during and after therapy]. 54 61
20198895 2009
33
Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis. 54 61
19897681 2009
34
IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C. 61 54
19797428 2009
35
Resolution of preoperative portal vein thrombosis after administration of antithrombin III in living donor liver transplantation: case report. 54 61
19917415 2009
36
Comparison of the effect of BCAA granules on between decompensated and compensated cirrhosis. 54 61
20214224 2009
37
A novel nonsynonymous variant of matrix metalloproteinase-7 confers risk of liver cirrhosis. 61 54
19676133 2009
38
Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis. 61 54
19243500 2009
39
Correlation of routinely used coagulation parameters and presence of portal vein thrombosis in patients with liver cirrhosis. 54 61
19619258 2009
40
Endothelial to mesenchymal transition via transforming growth factor-beta1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension. 54 61
19608867 2009
41
Twenty-year survivors after resection for hepatocellular carcinoma-analysis of 53 cases. 61 54
19294419 2009
42
Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. 54 61
19642174 2009
43
[Analysis of prognostic factors for patients with acute-on-chronic liver failure]. 54 61
19719920 2009
44
Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. 61 54
19413694 2009
45
Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. 54 61
19365625 2009
46
[Comparison of the serum proteomes of pathological stages during hepatocarcinogenesis]. 54 61
19912687 2009
47
Cytokine evaluation in liver cirrhosis and hepatocellular carcinoma. 61 54
19760951 2009
48
Milder liver cirrhosis and loss of serum HBeAg do not imply lower risk for hepatocellular carcinoma development in HBV-related cirrhosis. 61 54
19478697 2009
49
Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis. 61 54
19201777 2009
50
Altered basal and postprandial plasma melatonin, gastrin, ghrelin, leptin and insulin in patients with liver cirrhosis and portal hypertension without and with oral administration of melatonin or tryptophan. 54 61
19552764 2009
Sources

Variations for Liver Cirrhosis

About this section

ClinVar genetic disease variations for Liver Cirrhosis:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 KRT8 NM_002273.4(KRT8):c.160T>C (p.Tyr54His) SNV Pathogenic, risk factor 14631 rs57749775 12:53298606-53298606 12:52904822-52904822
2 FARSB NM_005687.5(FARSB):c.1381A>C (p.Thr461Pro) SNV Pathogenic 545642 rs1396171148 2:223478611-223478611 2:222613892-222613892
3 FARSB NM_005687.5(FARSB):c.784A>G (p.Lys262Glu) SNV Pathogenic 545655 rs1553554543 2:223496325-223496325 2:222631606-222631606
4 FARSB NM_005687.5(FARSB):c.1202G>A (p.Arg401Gln) SNV Pathogenic 545664 rs1553553086 2:223488418-223488418 2:222623699-222623699
5 FARSB NM_005687.5(FARSB):c.755T>C (p.Phe252Ser) SNV Pathogenic 545694 rs1466642025 2:223496354-223496354 2:222631635-222631635
6 FARSB NM_005687.5(FARSB):c.226T>C (p.Cys76Arg) SNV Pathogenic 545695 rs1419129874 2:223507613-223507613 2:222642894-222642894
7 KRT8 NM_002273.4(KRT8):c.184G>T (p.Gly62Cys) SNV Pathogenic 14630 rs11554495 12:53298582-53298582 12:52904798-52904798
8 LOC106096416 NM_000224.3(KRT18):c.383A>T (p.His128Leu) SNV Pathogenic 14585 rs57758506 12:53343340-53343340 12:52949556-52949556
9 LOC106096416 NM_000224.3(KRT18):c.383A>T (p.His128Leu) SNV risk factor 14585 rs57758506 12:53343340-53343340 12:52949556-52949556
10 KRT8 NM_002273.4(KRT8):c.184G>T (p.Gly62Cys) SNV risk factor 14630 rs11554495 12:53298582-53298582 12:52904798-52904798

Copy number variations for Liver Cirrhosis from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 210504 6 30400000 36600000 Copy number C4B Liver cirrhosis
Sources

Expression for Liver Cirrhosis

About this section
Search GEO for disease gene expression data for Liver Cirrhosis.
Sources

Pathways for Liver Cirrhosis

About this section

Pathways related to Liver Cirrhosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.05 SERPINA1 HGF ALB AFP
2
FOXA2 and FOXA3 transcription factor networks 1
10.78 F2 ALB AFP
3
LncRNA-mediated mechanisms of therapeutic resistance 1
10.23 MEG3 HOTAIR
Sources

GO Terms for Liver Cirrhosis

About this section

Cellular components related to Liver Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.46 SERPINA1 F2 ALB AFP
2 extracellular space GO:0005615 9.32 SERPINA1 REN IFNA1 HGF HFE GPT
3 platelet alpha granule lumen GO:0031093 9.13 SERPINA1 HGF ALB

Biological processes related to Liver Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.26 SERPINA1 F2 ALB AFP
2 acute-phase response GO:0006953 8.8 SERPINA1 HFE F2
Sources

Sources for Liver Cirrhosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....